Navigation Links
Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting
Date:11/19/2010

MONTREAL, CANADA - November 19, 2010 - Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy. Professor Zvi Ram, chairman of the Department of Neurosurgery at Tel-Aviv Sourasky Medical Center, presented the data at the Society for Neuro-Oncology (SNO) Annual Scientific Meeting.

Physicians delivered the investigational TTF therapy to patients in the study using the NovoTTF-100A a portable, non-invasive medical device. Investigators conducted this phase III study under an approved IDE at 28 centers in the US, Europe, and Israel, enrolling 237 patients with glioblastoma tumors that had recurred or progressed after initial treatment. Patients randomly received TTF therapy alone or an effective chemotherapy selected by physicians. The results reported today expand on headline data from the trial presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in June 2010, which suggested that TTF therapy may be as effective as the best available chemotherapy in extending overall survival of patients with recurrent GBM.

"The study suggests that patients treated with TTF therapy, as defined in the protocol, lived significantly longer than patients treated with the currently available best chemotherapeutic regimens," said Professor Ram. "Interestingly, younger patients and patients with better functional status appear to have an impressive survival advantage. In these patients the incidence of radiological tumor response to TTF therapy was double that seen in patients treated with chemotherapy. Most importantly, in addition to the survival benefit, treatment with TTF therapy was associated with significantly better quality of life compared to patients receiving chemotherapy."

Patients under the age of 60 who were able to maintain normal daily activities (KPS>80 percent) at the time of enrollment achieved a significant increase in median overall survival time (8.8 vs. 6.6 months, n=110, p< 0.01) and in the 1-year survival rate (35 percent vs. 20 percent, n=110, p< 0.01) when treated with TTF Therapy versus effective chemotherapies. TTF therapy also produced a significant increase in survival time for patients who had failed treatment with bevacizumab (Avastin; Roche) prior to enrollment (4.4 vs. 3.1 months, n=44, p< 0.02). Patients enrolled in the study also reported superior quality of life scores (EORTC QLQ-C30) across a range of lifestyle and symptom categories for TTF therapy compared to the chemotherapy-treated control group.

"The data presented at SNO further validate TTF therapy as a potential treatment option for patients with recurrent glioblastoma tumors," said Asaf Danziger, chief executive officer of Novocure, the trial sponsor. "The suggested improvement in quality of life scores reported by patients receiving TTF therapy is particularly important given the nature of this disease and the strong desire among patients and their caregivers to avoid the side-effects of chemotherapy and radiation."

TTF therapy has been shown in vitro to slow and reverse tumor cell proliferation by inhibiting mitosis, the process by which cells divide and replicate. The NovoTTF-100A device, which weighs about six pounds (three kilograms), creates a low-intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division.

Novocure is now sponsoring a second phase III study of TTF therapy at 26 centers in the US, Europe, and Israel. This study will enroll 283 patients with newly diagnosed glioblastoma tumors. Patients will be randomized (2 to 1) to receive TTF therapy and temozolomide (Temodar; Merck & Co) or temozolomide alone (the current best standard of care).

Novocure also recently reported results from a successful phase II trial that studied TTF therapy in combination with chemotherapy for advanced non-small cell lung cancer at the European Society of Medical Oncology Congress.

The NovoTTF-100A is an investigational device in the United States and has not been approved by the U.S. Food and Drug Administration (FDA) for sale in the US for any use. Results of this phase III trial for recurrent glioblastoma patients have been submitted in a premarket approval application, which is under review by FDA. Novocure currently has CE Mark for the NovoTTF-100A and the treatment is available to patients in Europe.


'/>"/>

Contact: Frank Leonard
frank@novo-cure.com
917-656-3518
Edelman Public Relations
Source:Eurekalert

Related medicine news :

1. Professor John Shine wins 2010 Prime Ministers Prize for Science
2. CancerCare names Jefferson professor Physician of the Year
3. Professor Cesare Montecucco to receive the 2011 Paul Ehrlich and Ludwig Darmstaedter Prize
4. UT professor defines play, discovers even turtles need recess
5. Virginia Tech professor discovers new TB pathogen
6. Drug to treat alcoholism goal of UH professors research
7. K-State professors book is first to explore Two-Spirit literature in Northwest native groups
8. Louisiana Tech kinesiology professor receives national editorial excellence award
9. WPI computer science professor receives HP Labs Innovation Research Award
10. Linguistics professor examines manufacturers prescription drug websites
11. NJIT professor heads panel studying sudden car acceleration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
Breaking Medicine Technology: